Healthcare, Pharma & Life Sciences

Austin, Texas – November 05, 2026 -- Genprex (NASDAQ: GNPX) reported that whole-blood analysis of 11 lung cancer patients treated with its gene therapy REQORSA (quaratusugene ozeplasmid) showed a shift toward mitochondrial adaptation, autophagy and protein quality control 24 hours after infusion. The company presented the findings at the Gerontological Society of America (GSA) 2026 Annual Scientific Meeting, held November 4-7 in National Harbor, Maryland.

Blood samples from two REQORSA trials show a two-phase response

The patients were enrolled in two clinical trials evaluating REQORSA. Researchers collected whole-blood transcriptomes before treatment and at 5 and 24 hours after intravenous administration. They compared the 0-5, 5-24 and 0-24 hour intervals to separate the acute response to delivery from the sustained cellular-remodeling program.

WUXI – November 05, 2026 -- NORROY BIOSCIENCE presented its radiopharmaceutical pipelines in eight Top Rated Oral Presentations and three e-posters at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM'26), held October 17-21 in Vienna, Austria. The China-based, late-stage clinical biotech also reached preliminary cooperation intentions with Esente Healthcare and other international partners on radiopharmaceutical automation equipment.

Cantanhede – November 05, 2026 -- Mondego Bio has started a first-in-human Phase 1 study of MB-388, an oral dual PTPN2/PTPN1 inhibitor built to overcome resistance to cancer immunotherapy, with initial human pharmacokinetic and pharmacodynamic data due in December 2026.

Phase 1a tests dose escalation in healthy volunteers

The randomized, double-blind, placebo-controlled study will evaluate single and multiple ascending doses of MB-388. It will assess safety and tolerability, characterize pharmacokinetics and measure target engagement using blood-based pharmacodynamic biomarkers.

CEO Nikolay Savchuk said the study will define the relationship between exposure, pathway engagement and tolerability ahead of the planned patient study.

Gaithersburg – November 05, 2026 -- Novavax raised its full-year 2026 Non-GAAP Adjusted Total Revenue guidance by $145 million to $400 million at the mid-point, after earning a $125 million milestone from partner Sanofi and cutting its quarterly net loss to $31 million from $202 million a year earlier.

Sanofi's European Phase 3 start triggers $125 million payment

Novavax earned the payment in October, when Sanofi initiated a Phase 3 trial of its influenza-COVID-19 combination (CIC) vaccine in Europe. Sanofi has confirmed it intends to start a U.S. Phase 3 CIC trial in 2027 to support U.S. approval.

SARASOTA – November 05, 2026 -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) paid $1,270,970 in cash to redeem all 127,097 remaining shares of its Series C Convertible Preferred Stock, leaving the clinical-stage company with no preferred equity outstanding.

Redemption with Shakawe Capital closes under a November 2 agreement

The transaction was executed under a redemption agreement dated November 2, 2026, with Shakawe Capital LLC. The company funded the payment from cash on hand.

Conversion dilution risk is eliminated

No Series C shares remain outstanding, so no additional common shares will be issuable upon conversion. The redemption also removes all restrictions tied to the instrument. Lakewood-Amedex reports no outstanding indebtedness for borrowed money.

CEO Kelvin Cooper said the move "simplifies our capital structure" and gives the company greater financial flexibility as it advances its development programs.

Mainz – November 05, 2026 -- Germany's Federal Guild of Hearing Acousticians (biha) warns that the draft Hilfsmittelmodernisierungs- und Bürokratieabbaugesetz (HiB) could push small and mid-sized hearing care businesses into insolvency by delaying their payments for weeks or months.

Draft law gives statutory insurers control over all hearing system fittings

The bill would introduce stronger oversight of every hearing system provision, carried out by the statutory health insurers (GKV). According to biha, insurers would have to approve fittings even where the patient already holds a specialist medical prescription.

PROVIDENCE – November 05, 2026 -- Electronic Genome Mapping (EGM) detected every abnormality identified by standard cytogenetic testing in an initial study, according to researchers from Augusta University and The University of Texas MD Anderson Cancer Center. They will present the findings at the Association for Molecular Pathology (AMP) 2026 Annual Meeting, November 10-14 in Seattle, Nabsys 2.0, LLC said.

Augusta and MD Anderson pathologists present EGM data on November 13

Ravindra Kolhe, M.D., Ph.D., Professor and Chair of Pathology at Augusta University, and Rashmi Kanagal-Shamanna, M.D., Professor of Hematopathology and Molecular Diagnostics at MD Anderson, will present at the Innovation Spotlight Session (stage 1). The slot runs 9:30-10:00 a.m. PT on Friday, November 13. The talk is titled "Electronic Genome Mapping for Structural Variant Detection: Implications for Advancing Clinical Research in Heme Malignancies."

Philadelphia – November 05, 2026 -- The share of US newborns not receiving the routine intramuscular vitamin K injection more than doubled between 2017 and 2025, rising from 3.1% to 6.8%, according to a Children's Hospital of Philadelphia (CHOP) study published in JAMA. It is the largest retrospective analysis of the trend to date, covering more than 5.2 million hospital births.

Infants without the injection showed a 47% higher risk of bleeding

Researchers analyzed deidentified electronic health record data from hospitals and clinics in all 50 states and Washington, D.C. The cohort included infants born at 35 to 43 weeks' gestation and followed them through their first six months of life. Of these, 234,825 infants (4.5%) did not receive intramuscular vitamin K at birth.

SAN MATEO – November 05, 2026 -- Astrosalva Therapeutics, a privately held preclinical biotech developing treatments for Alexander disease and the cerebral form of adrenoleukodystrophy (cALD), has appointed Wendy Erler, Senior Vice President of Patient Affairs at Sarepta Therapeutics, as the first member of its Strategic Advisory Board.

Erler to steer patient engagement and trial planning at Astrosalva

Erler will advise on patient and community engagement strategy. Her remit includes working with existing community natural history registries and bringing patient and caregiver perspectives into future clinical trial planning.

Co-founder and CEO Paul Schmidt said the order of announcements is deliberate: Erler is the first advisor named, because the company wants families to know it is being built around patients and their communities.

Valencia – November 04, 2026 -- ARTHEx Biotech, a clinical-stage RNA therapeutics developer, has appointed Christian (Chris) Freitag, M.D., as Chief Medical Officer, adding more than 20 years of clinical development experience to a pipeline led by ATX-01 for myotonic dystrophy type 1 (DM1).

Freitag arrives from CMO roles at Azafaros and Dynacure

Freitag most recently served as Chief Medical Officer at Azafaros, which develops treatments for rare genetic disorders. Before that, he was CMO at Dynacure, where he was responsible for medical and regulatory strategy, including clinical development of the company's lead investigational therapy for centronuclear myopathies.